BioSpace News Archive

Teva Announces New Findings Highlighting Potential of ProAir ® Digihaler ® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges.

scPharmaceuticals Inc. announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24 at 3:00pm EDT, at the Fontainebleau Miami Beach Hotel in Miami, FL.

AUM Biosciences, a global clinical-stage biotech company focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced the appointment of Scott Jordan, BA, MBA, as Head of Corporate Development.

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company’s Board of Directors, effective immediately.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 11:00 a.m. ET in Miami, FL.

Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the dosing of the first patient in the Company’s sponsored research of the Center for Definitive and Curative Medicine (CDCM) at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia.

Agile Therapeutics, Inc. will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL.

Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, announced that management will present at the H.C. Wainwright Global Investment Conference being held May 23 through May 26, 2022.

Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference.

Selecta Biosciences, Inc. announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.